MiRNA-200b reverses drug resistance of hepatocellular carcinoma HepG2 cells to sorafenib and its underlying mechanism
Objective To explore the effect of miRNA-200b on sorafenib resistance in hepatocellular carcinoma cells in order to increase the efficacy of the drug in advanced liver cancer patients. Methods Sorafenib resistant hepatocellular carcinoma HepG2-SR cell line was established by gradually increasing th...
Guardado en:
Autores principales: | DENG Yong, TANG Tengqian, ZHANG Leida |
---|---|
Formato: | article |
Lenguaje: | ZH |
Publicado: |
Editorial Office of Journal of Third Military Medical University
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ebebf18ffa6548c1a4574feac02cd3e2 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Prediction of early recurrence and response to adjuvant Sorafenib for hepatocellular carcinoma after resection
por: Liming Zheng, et al.
Publicado: (2021) -
Design And Characterisation Of Novel Sorafenib-Loaded Carbon Nanotubes With Distinct Tumour-Suppressive Activity In Hepatocellular Carcinoma
por: Elsayed MMA, et al.
Publicado: (2019) -
Sorafenib-Loaded Nanoparticles Based on Biodegradable Dendritic Polymers for Enhanced Therapy of Hepatocellular Carcinoma
por: Li Z, et al.
Publicado: (2020) -
Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib
por: Pomej K, et al.
Publicado: (2021) -
ABCC5 facilitates the acquired resistance of sorafenib through the inhibition of SLC7A11-induced ferroptosis in hepatocellular carcinoma
por: Wenbin Huang, et al.
Publicado: (2021)